hyperCORE International has announced Nicholas Focil as its new president, a decision that underscores the network's commitment to advancing global clinical research. With nearly 20 years of experience in clinical operations and strategic partnerships, Focil's leadership is expected to propel hyperCORE's mission of conducting ethical, high-quality, and diverse clinical trials.
Focil, the founder and CEO of FOMAT Medical Research, brings a wealth of experience from his work in over 70 therapeutic areas across the U.S. and Latin America. His focus on trial diversity and community engagement aligns with hyperCORE's values, making him an ideal candidate to lead the network into its next phase of growth.
The outgoing president, Carlos Orantes, praised Focil's appointment as a milestone for hyperCORE, highlighting the importance of continuity and excellence in leadership. Focil expressed gratitude for Orantes's contributions and outlined his vision for enhancing site capabilities and expanding the reach of clinical trials to benefit patients and sponsors alike.
hyperCORE International, established in 2019, is a network of over 80 active trial sites across five countries, known for its operational excellence and commitment to ethical research. Focil's leadership comes at a pivotal time as the organization seeks to build on its legacy of innovation and patient-centered care in the dynamic field of clinical research.
